The evidence that the Royal Marsden Hospital score or the MD Anderson prognostic score could not be used to predict outcomes of the patients with KRAS+/TP53+ mutant cancer who received a phase I clinical trial therapy may indicate that the outcome was related to their unique biological characteristics, and availability of effective phase I trial therapy. Here, KRAS is linked to cancer.